Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

This phase Ib study evaluated the safety, pharmacokinetics, and activity of enzastaurin either 500 mg once daily (QD) or 250 mg twice daily (b.i.d.) in combination with pemetrexed. Pemetrexed 500 mg/m2 with folic acid and vitamin B12 was given on day 1 every 21 days with enzastaurin 500 mg orally QD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2009-09, Vol.20 (9), p.1565-1575
Hauptverfasser:	Hanauske, A.-R., Lahn, M., Musib, L.C., Weigang-Köhler, K., Yilmaz, E., Graefe, T., Kuenen, B., Thornton, D., McNealy, P., Giaccone, G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics enzastaurin Female Glutamates - administration & dosage Glutamates - adverse effects Glutamates - pharmacokinetics Guanine - administration & dosage Guanine - adverse effects Guanine - analogs & derivatives Guanine - pharmacokinetics Humans Indoles - administration & dosage Indoles - adverse effects Indoles - pharmacokinetics Male Middle Aged Neoplasms - drug therapy Pemetrexed pharmacokinetics phase I safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!